OncoDaily covers a GCOS 2026 talk on where artificial intelligence and GLP-1 drugs could take heart care for cancer patients.
Recap by typeshit. Post by @oncodaily on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The forecast puts 2025 sales at $45.8 billion, with Zepbound's $22.9 billion edging past Wegovy's $18.6 billion last year.
An emergency physician shares a short, pointed reaction to claims that RUO products are a safe route, with a link to more.
Loading…